Schering Drug Patent Portfolio
Schering owns 2 orange book drugs protected by 16 US patents Given below is the list of Schering's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6790837 | Ribavirin syrup formulations | 05 Oct, 2023 | Expired |
| US6790837 | Ribavirin syrup formulations | 05 Apr, 2023 | Expired |
| US8263600 | Antifungal composition with enhanced bioavailability | 01 Apr, 2022 | Expired |
| US5661151 | Tetrahydrofuran antifungals | 19 Jul, 2019 | Expired |
| US6958337 | Crystalline antifungal polymorph | 05 Oct, 2018 | Expired |
| US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection | 21 Mar, 2018 | Expired |
| US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection | 21 Mar, 2018 | Expired |
| US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection | 21 Sep, 2017 | Expired |
| US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection | 21 Sep, 2017 | Expired |
| US6177074 | Polyethylene glycol modified interferon therapy | 01 May, 2017 | Expired |
| US6461605 | Continuous low-dose cytokine infusion therapy | 01 May, 2017 | Expired |
| US6524570 | Polyethylene glycol modified interferon therapy | 01 May, 2017 | Expired |
| US6177074 | Polyethylene glycol modified interferon therapy | 01 Nov, 2016 | Expired |
| US6461605 | Continuous low-dose cytokine infusion therapy | 01 Nov, 2016 | Expired |
| US6524570 | Polyethylene glycol modified interferon therapy | 01 Nov, 2016 | Expired |
| US5703079 | Tetrahydrofuran antifungals | 26 Aug, 2014 | Expired |
Latest Legal Activities on Schering's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Schering.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 8th Year, Large Entity | 30 Apr, 2024 | US9493582 |
|
Maintenance Fee Reminder Mailed
Critical
| 29 Apr, 2024 | US8263600 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 10 Nov, 2023 | US9358297 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9750822 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US10117951 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US8410077 |
|
Correspondence Address Change
Critical
| 04 Dec, 2022 | US9493582 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 12 Oct, 2022 | US9023790 (Litigated) |
| Payment of Maintenance Fee, 4th Year, Large Entity | 20 Apr, 2022 | US10117951 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 17 Feb, 2021 | US9750822 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 17 Sep, 2020 | US8410077 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 30 Apr, 2020 | US9493582 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Feb, 2020 | US8263600 |
| Payment of Maintenance Fee, 4th Year, Large Entity | 18 Nov, 2019 | US9358297 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 06 Nov, 2018 | US10117951 |
Schering's Family Patents
Schering drugs have patent protection in a total of 26 countries. It's US patent count contributes only to 13.7% of its total global patent coverage. 17 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click
below to unlock the full patent family tree.
Schering Drug List
Given below is the complete list of Schering's drugs and the patents protecting them.
1. Noxafil
Noxafil is protected by 4 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8263600 | Antifungal composition with enhanced bioavailability |
01 Apr, 2022
(3 years ago)
| Expired |
| US5661151 | Tetrahydrofuran antifungals |
19 Jul, 2019
(5 years ago)
| Expired |
| US6958337 | Crystalline antifungal polymorph |
05 Oct, 2018
(6 years ago)
| Expired |
| US5703079 | Tetrahydrofuran antifungals |
26 Aug, 2014
(10 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Noxafil's drug page
2. Rebetol
Rebetol is protected by 12 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US6790837
(Pediatric)
| Ribavirin syrup formulations |
05 Oct, 2023
(1 year, 7 months ago)
| Expired |
| US6790837 | Ribavirin syrup formulations |
05 Apr, 2023
(2 years ago)
| Expired |
| US6172046
(Pediatric)
| Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
21 Mar, 2018
(7 years ago)
| Expired |
| US6472373
(Pediatric)
| Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
21 Mar, 2018
(7 years ago)
| Expired |
| US6172046 | Combination therapy for eradicating detectable HCV-RNA in patients having chronic Hepatitis C infection |
21 Sep, 2017
(7 years ago)
| Expired |
| US6472373 | Combination therapy for eradicating detectable HCV-RNA in antiviral treatment naive patients having chronic hepatitis C infection |
21 Sep, 2017
(7 years ago)
| Expired |
| US6177074
(Pediatric)
| Polyethylene glycol modified interferon therapy |
01 May, 2017
(8 years ago)
| Expired |
| US6461605
(Pediatric)
| Continuous low-dose cytokine infusion therapy |
01 May, 2017
(8 years ago)
| Expired |
| US6524570
(Pediatric)
| Polyethylene glycol modified interferon therapy |
01 May, 2017
(8 years ago)
| Expired |
| US6177074 | Polyethylene glycol modified interferon therapy |
01 Nov, 2016
(8 years ago)
| Expired |
| US6461605 | Continuous low-dose cytokine infusion therapy |
01 Nov, 2016
(8 years ago)
| Expired |
| US6524570 | Polyethylene glycol modified interferon therapy |
01 Nov, 2016
(8 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Rebetol's drug page
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List